• Biotin-HPDP for Reversible Thiol Mapping

  2026-08-21

  Biotin-HPDP enables reversible thiol-specific protein labeling for redox and lipidation studies. This article connects its assay chemistry to the SELENOK–CD36 pathway in microglial Aβ phagocytosis and explains how to interpret capture results without confusing labeling with biological causality.

• Spatial Sampling of Disease in Ambrosia Beetle Colonies

  2026-08-20

  This open-access STAR Protocols paper presents an integrated workflow for rearing Xyleborus affinis, applying Metarhizium infection assays, testing vertical and horizontal transmission, and mapping microbes across colony habitats. Its main contribution is methodological: combining spatial sampling, culturable microbial quantification, fluorescence imaging, and cryo-sectioning to make infection dynamics in social beetle colonies experimentally tractable.

• Galectin-1–FIP200 Axis in Hepatic Steatosis

  2026-08-20

  A 2026 study identifies galectin-1 as an upstream suppressor of hepatic autophagy that promotes steatosis, dyslipidemia, and insulin resistance through direct interaction with FIP200. By combining mouse models, proteomics, binding analysis, structural mapping, and interaction-disrupting mutations, the work defines the Gal-1–FIP200 axis as a mechanistic target for metabolic liver disease research.

• Ionophore Toxicity in Animals: Mechanisms and Risk

  2026-08-19

  Ekinci, Chłodowska, and Olejnik integrate clinical observations with molecular evidence to explain how polyether ionophores disrupt ion gradients, oxidative phosphorylation, and muscle-cell integrity in animals. The review also highlights species, age, dose, and tiamulin-interaction effects, providing a framework for safer veterinary study design and interpretation.

• Alpha-Ketoglutarate Workflows in Tumor Metabolism

  2026-08-19

  Use alpha-ketoglutarate as a controlled metabolic perturbation to connect TCA-cycle flux, nitrogen handling, enzyme activity, and macrophage signaling. This workflow translates a cholangiocarcinoma study into practical assay designs, concentration planning, controls, and troubleshooting steps for reproducible metabolic reprogramming research.

• Bazedoxifene as an Antimalarial: Hemozoin Inhibition

  2026-08-18

  The reference study identifies bazedoxifene, a third-generation selective estrogen receptor modulator, as an inhibitor of Plasmodium growth in erythrocytes and mice. Its strongest activity occurred during the ring stage and was associated with reduced hemozoin formation, supporting drug repurposing while highlighting sex-dependent differences in host-mediated efficacy.

• O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-08-18

  The reference study identifies O-GlcNAcylation as a metabolic and post-translational mechanism through which Wnt3a promotes osteoblastogenesis and bone repair. Its central finding is that Wnt stabilizes PDK1 through modification at Ser174, increasing aerobic glycolysis and linking Wnt signaling to glucose metabolism.

• Developmental SSRI Exposure and Motivation Deficits

  2026-08-17

  A 2026 Columbia dissertation shows that developmental SSRI exposure produces a selective motivational deficit in adolescent and adult mice, while reward liking and Pavlovian learning remain comparatively intact. Its most distinctive finding is that mu opioid receptor antagonism or nucleus accumbens knockdown can attenuate the deficit, identifying opioid-reward circuitry as a potential mechanistic target distinct from repeated SSRI treatment.

• SMYD2, miR-125b, and Drug Resistance in ccRCC

  2026-08-17

  The 2019 Theranostics study identifies SMYD2 as a prognostic and functional driver of clear cell renal cell carcinoma, linking its activity to the miR-125b/DKK3 pathway and P-glycoprotein-mediated multidrug resistance. Its combination of patient-prognostic analysis, epigenetic profiling, mechanistic cell assays, drug-response testing, and xenograft validation provides a framework for studying resistance-modifying strategies in renal cancer.

• Cirsium setidens Protects Against Doxorubicin Cardiotoxicity

  2026-08-16

  A 2024 Phytomedicine study shows that a hydroethanolic extract of Cirsium setidens protects cardiomyocytes from Doxorubicin-associated mitochondrial injury through an AMPK–PGC-1α–NRF1–SOD axis. The extract reduced cardiac toxicity in cellular, mouse, and human iPSC-derived cardiomyocyte models while preserving Doxorubicin-induced death in a breast cancer model.

• Plk1 Control of p31comet in Mitotic Checkpoint Exit

  2026-08-15

  The reference study identifies Polo-like kinase 1 as a negative regulator of p31comet-driven mitotic checkpoint complex disassembly. By combining HeLa cell extracts, purified proteins, kinase inhibition, and an S102A mutant, the authors show how Plk1 phosphorylation restrains checkpoint termination during mitotic arrest.

• Sodium Ascorbate: Designing Redox-Immune Assays

  2026-08-14

  Sodium Ascorbate can do more than generate oxidative stress in cancer models. This article presents an assay-design framework that connects redox-mediated tumor-cell injury with biomarker-rich immunotherapy research while defining the limits of that cross-domain interpretation.

• Demethyleneberberine: Mitochondrial Assay Strategy

  2026-08-14

  Demethyleneberberine (DMB) is more than a broad anti-inflammatory natural product: its strongest experimental value lies in resolving how TLR4, mitochondria, NLRP3, and IL-1β maturation interact. This article translates that mechanism into practical assay design, controls, dosing logic, and cross-disease interpretation.

• Mc-Val-Cit-PABC-PNP: ADC Workflow Guide

  2026-08-13

  Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable peptide linker for antibody-drug conjugate workflows that require lysosomal payload release. This guide covers solvent selection, material calculations, conjugation planning, and QC while defining its limits: the free linker is insoluble in water and ethanol, solutions should be used promptly, and the product is for research use only.

• Nuclear cGAS Restricts LINE-1 Retrotransposition

  2026-08-13

  The reference study identifies a nuclear genome-protection function for cGAS: it suppresses LINE-1 retrotransposition by promoting TRIM41-dependent ubiquitination and degradation of ORF2p. Its DNA-damage-responsive CHK2–cGAS–TRIM41–ORF2p axis connects innate immune signaling, transposon control, aging, and tumorigenesis while also defining testable limitations for pharmacological DNA damage response studies.

8063 records 8/538 page Previous Next First page 上5页 678910 下5页 Last page